Bank of New York Mellon’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $831M | Buy |
1,672,623
+86,196
| +5% | +$38.2M | 0.14% | 136 |
|
|
2026
Q1 | $708M | Buy |
1,586,427
+58,841
| +4% | +$27.4M | 0.13% | 154 |
|
|
2025
Q4 | $693M | Sell |
1,527,586
-41,579
| -3% | -$17.9M | 0.12% | 156 |
|
|
2025
Q3 | $615M | Sell |
1,569,165
-31,308
| -2% | -$13.1M | 0.11% | 164 |
|
|
2025
Q2 | $713M | Sell |
1,600,473
-111,192
| -6% | -$51.2M | 0.13% | 145 |
|
|
2025
Q1 | $830M | Sell |
1,711,665
-47,551
| -3% | -$22.2M | 0.16% | 121 |
|
|
2024
Q4 | $708M | Sell |
1,759,216
-27,512
| -2% | -$12.8M | 0.13% | 144 |
|
|
2024
Q3 | $831M | Sell |
1,786,728
-50,922
| -3% | -$24.5M | 0.15% | 125 |
|
|
2024
Q2 | $861M | Sell |
1,837,650
-36,479
| -2% | -$15.8M | 0.16% | 115 |
|
|
2024
Q1 | $783M | Sell |
1,874,129
-102,859
| -5% | -$43.5M | 0.15% | 131 |
|
|
2023
Q4 | $804M | Sell |
1,976,988
-36,908
| -2% | -$13.6M | 0.16% | 126 |
|
|
2023
Q3 | $700M | Buy |
2,013,896
+16,439
| +0.8% | +$5.75M | 0.15% | 128 |
|
|
2023
Q2 | $703M | Sell |
1,997,457
-40,447
| -2% | -$13.6M | 0.15% | 128 |
|
|
2023
Q1 | $642M | Sell |
2,037,904
-44,395
| -2% | -$13.3M | 0.14% | 138 |
|
|
2022
Q4 | $601M | Buy |
2,082,299
+829
| +0% | +$253K | 0.14% | 151 |
|
|
2022
Q3 | $603M | Sell |
2,081,470
-16,831
| -0.8% | -$4.84M | 0.15% | 138 |
|
|
2022
Q2 | $591M | Buy |
2,098,301
+95,436
| +5% | +$25.5M | 0.14% | 146 |
|
|
2022
Q1 | $523M | Sell |
2,002,865
-59,941
| -3% | -$14.2M | 0.1% | 179 |
|
|
2021
Q4 | $453M | Sell |
2,062,806
-25,982
| -1% | -$5.05M | 0.08% | 211 |
|
|
2021
Q3 | $379M | Sell |
2,088,788
-25,930
| -1% | -$5.06M | 0.07% | 233 |
|
|
2021
Q2 | $426M | Sell |
2,114,718
-33,948
| -2% | -$7.1M | 0.08% | 212 |
|
|
2021
Q1 | $462M | Sell |
2,148,666
-133,222
| -6% | -$29.3M | 0.09% | 192 |
|
|
2020
Q4 | $539M | Sell |
2,281,888
-315,296
| -12% | -$72.3M | 0.12% | 152 |
|
|
2020
Q3 | $707M | Buy |
2,597,184
+87,014
| +3% | +$24M | 0.17% | 108 |
|
|
2020
Q2 | $729M | Buy |
2,510,170
+17,545
| +0.7% | +$4.76M | 0.19% | 100 |
|
|
2020
Q1 | $593M | Sell |
2,492,625
-16,775
| -0.7% | -$3.85M | 0.2% | 105 |
|
|
2019
Q4 | $549M | Sell |
2,509,400
-72,194
| -3% | -$14.6M | 0.14% | 137 |
|
|
2019
Q3 | $437M | Buy |
2,581,594
+3,444
| +0.1% | +$609K | 0.12% | 164 |
|
|
2019
Q2 | $473M | Buy |
2,578,150
+296,068
| +13% | +$51.8M | 0.13% | 151 |
|
|
2019
Q1 | $420M | Buy |
2,282,082
+76,930
| +3% | +$14.2M | 0.12% | 159 |
|
|
2018
Q4 | $365M | Sell |
2,205,152
-124,886
| -5% | -$21.6M | 0.11% | 164 |
|
|
2018
Q3 | $449M | Sell |
2,330,038
-557
| -0% | -$99.2K | 0.12% | 167 |
|
|
2018
Q2 | $396M | Sell |
2,330,595
-21,447
| -0.9% | -$3.32M | 0.11% | 179 |
|
|
2018
Q1 | $383M | Buy |
2,352,042
+332,476
| +16% | +$54.3M | 0.11% | 191 |
|
|
2017
Q4 | $303M | Buy |
2,019,566
+25,156
| +1% | +$3.72M | 0.08% | 252 |
|
|
2017
Q3 | $303M | Buy |
1,994,410
+12,454
| +0.6% | +$1.87M | 0.08% | 247 |
|
|
2017
Q2 | $255M | Sell |
1,981,956
-102,277
| -5% | -$12.3M | 0.07% | 276 |
|
|
2017
Q1 | $228M | Buy |
2,084,233
+5,611
| +0.3% | +$494K | 0.06% | 324 |
|
|
2016
Q4 | $153M | Sell |
2,078,622
-957,092
| -32% | -$77.9M | 0.04% | 420 |
|
|
2016
Q3 | $265M | Buy |
3,035,714
+13,278
| +0.4% | +$1.25M | 0.08% | 269 |
|
|
2016
Q2 | $260M | Sell |
3,022,436
-143,602
| -5% | -$12.4M | 0.08% | 263 |
|
|
2016
Q1 | $252M | Sell |
3,166,038
-432,400
| -12% | -$39.1M | 0.08% | 270 |
|
|
2015
Q4 | $453M | Sell |
3,598,438
-287,256
| -7% | -$34.7M | 0.14% | 156 |
|
|
2015
Q3 | $405M | Sell |
3,885,694
-456,855
| -11% | -$58.7M | 0.12% | 167 |
|
|
2015
Q2 | $536M | Sell |
4,342,549
-125,066
| -3% | -$15.8M | 0.15% | 140 |
|
|
2015
Q1 | $527M | Buy |
4,467,615
+556,777
| +14% | +$66.7M | 0.14% | 155 |
|
|
2014
Q4 | $465M | Buy |
3,910,838
+325,584
| +9% | +$36.7M | 0.12% | 178 |
|
|
2014
Q3 | $403M | Buy |
3,585,254
+259,581
| +8% | +$24.7M | 0.11% | 192 |
|
|
2014
Q2 | $315M | Buy |
3,325,673
+424,403
| +15% | +$29.8M | 0.08% | 252 |
|
|
2014
Q1 | $205M | Buy |
2,901,270
+101,001
| +4% | +$8M | 0.06% | 349 |
|
|
2013
Q4 | $208M | Sell |
2,800,269
-95,399
| -3% | -$6.64M | 0.06% | 334 |
|
|
2013
Q3 | $220M | Buy |
2,895,668
+223,252
| +8% | +$17.8M | 0.07% | 313 |
|
|
2013
Q2 | $214M | Buy |
+2,672,416
| New | +$197M | 0.07% | 306 |
|
Other funds holding VRTX
Bank of New York Mellon's VRTX Position: Q2 2026 in Review
Bank of New York Mellon increased its Vertex Pharmaceuticals (VRTX) stake by 5.4% in Q2 2026, buying an estimated $38.2M and bringing the position to 1,672,623 shares worth $831M. The position accounts for 0.14% of the portfolio, ranked #136.
Bank of New York Mellon first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $861M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Bank of New York Mellon held 1,672,623 shares of Vertex Pharmaceuticals worth $831M as of Q2 2026.
- Bank of New York Mellon bought 86,196 Vertex Pharmaceuticals shares in Q2 2026, an estimated $38.2M.
- Vertex Pharmaceuticals made up 0.14% of Bank of New York Mellon's portfolio in Q2 2026, its #136 holding.
- Bank of New York Mellon first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Vertex Pharmaceuticals position peaked at $861M in Q2 2024.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.